Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APORON buccal apomorphine pharmacokinetic, safety, and efficacy study in Parkinson's disease
NL-OMON52414Phase 2Active, not recruiting
- Sponsor
- Criceto
- Start
- Apr 2021
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of Aporon in Parkinson's disease (PD) (3 arms), sponsored by Criceto. Primary endpoints: Apomorphine plasma concentrations and derived pharmacokinetic parameters, Treatment-emergent adverse events and 5 more. Started Apr 2021; status: active, not recruiting.
02
Drugs
Aporon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON52414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52414.